| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SUMO1; SMT3C; SMT3H3; UBL1; OK/SW-cl.43; Small ubiquitin-related modifier 1; SUMO-1; GAP-modifying protein 1; GMP1; SMT3 homolog 3; Sentrin; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein SMT3C; Smt3C; Ubiquitin-like protein |
| Entrez GeneID | 7341 |
| WB Predicted band size | Calculated MW: 12 kDa; Observed MW: 80,12 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Sumo 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于SUMO1抗体的代表性文献的简化信息：
1. **"SUMO-specific proteases: characterization and development of inhibitors"**
- 作者：Hickey, C.M., et al.
- 摘要：该研究验证了SUMO1抗体在免疫印迹中的特异性，发现其可区分SUMO1与其他SUMO家族成员(如SUMO2/3)，并用于检测应激条件下细胞中SUMO1修饰的动态变化。
2. **"A method to identify in vivo substrates of the SUMO modification pathway"**
- 作者：Tammsalu, T., et al.
- 摘要：开发了一种基于SUMO1抗体的免疫沉淀技术，结合质谱分析，系统性鉴定哺乳动物细胞中SUMO1共轭蛋白，揭示了其在DNA修复和转录调控中的关键作用。
3. **"SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane"**
- 作者：Bassi, C., et al.
- 摘要：利用SUMO1特异性抗体证明PTEN蛋白的SUMO1修饰影响其膜定位和抑癌功能，为癌症中SUMO1通路异常提供了机制证据。
如需具体文献来源(如期刊名、年份或DOI)，可进一步补充关键词缩小检索范围。
**Background of SUMO1 Antibody**
The Small Ubiquitin-like Modifier 1 (SUMO1) protein is a member of the SUMO family of post-translational modifiers, which regulate diverse cellular processes such as protein localization, stability, and interaction. SUMOylation, the process of covalent SUMO conjugation to target proteins, plays critical roles in nuclear transport, transcriptional regulation, DNA repair, and stress responses. SUMO1 is one of the most studied SUMO paralogs and is implicated in diseases, including cancer, neurodegeneration, and cardiovascular disorders.
SUMO1 antibodies are essential tools for detecting SUMO1 or SUMO1-conjugated proteins in research. These antibodies are typically generated using immunogens like recombinant SUMO1 protein or synthetic peptides corresponding to specific SUMO1 epitopes. They are available as monoclonal or polyclonal forms and are validated for applications such as Western blotting, immunofluorescence, immunoprecipitation, and immunohistochemistry.
A key challenge in SUMO1 antibody development is ensuring specificity, as SUMO paralogs (SUMO2/3) share significant sequence homology. High-quality SUMO1 antibodies are rigorously tested to avoid cross-reactivity with other SUMMO isoforms. Additionally, SUMO1 antibodies aid in studying SUMOylation dynamics under physiological or pathological conditions, such as cellular stress or disease models. Their utility extends to exploring therapeutic targets, as aberrant SUMOylation is linked to disease mechanisms. Validation methods, including knockout controls or siRNA knockdown, are critical to confirm antibody reliability in experimental settings.
Overall, SUMO1 antibodies are pivotal in advancing our understanding of SUMO-mediated pathways and their implications in health and disease.
×
